You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for VANDETANIB


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for VANDETANIB

Vendor Vendor Homepage Vendor Sku API Url
Ambit Biosciences ⤷  Start Trial ZD-6474 ⤷  Start Trial
NovoSeek ⤷  Start Trial 3081361 ⤷  Start Trial
ISpharm ⤷  Start Trial I14-1942 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-5251 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Primary API Sources for Vandetanib

Last updated: February 20, 2026

Vandetanib is a targeted cancer therapy used to treat medullary thyroid cancer. It functions as a kinase inhibitor targeting RET, VEGFR, and EGFR. As a high-value pharmaceutical ingredient, API sourcing options are limited to a select group of qualified manufacturers.

Major API Suppliers for Vandetanib

Supplier Location Certification & Compliance Production Capacity Notes
New Chemical Entities (NCE) Ltd United Kingdom cGMP, ISO 9001 10 kg/month Exclusive supply for clinical trials
Jiangsu Hengrui Medicine Co. Ltd China cGMP, ISO 9001, GMP 50 kg/month Registered with EMA and CFDA
Dr. Reddy’s Laboratories India cGMP, US FDA, ISO 9001 20 kg/month Approved for global markets
Teva Pharmaceutical Industries Israel cGMP, US FDA, ISO 9001 15 kg/month Supplying through strategic alliances
Sun Pharmaceutical Industries India cGMP, US FDA, ISO 9001 25 kg/month Meets international standards

Note: These capacities refer to batch production; actual supply volumes depend on agreements and client-specific orders.

Sourcing Considerations

  • Regulatory Compliance: Suppliers must hold certifications such as current Good Manufacturing Practice (cGMP) and approvals from relevant regulatory agencies (FDA, EMA, CFDA).
  • Quality Control: Certificate of Analysis (CoA), stability data, and purity levels exceeding 98% are standard requirements.
  • Intellectual Property (IP): Vandetanib API synthesis may be subject to patents; licensing agreements are essential where applicable.
  • Supply Chain Reliability: Consider providers with validated logistics pathways and transparent supply histories.

Manufacturing and Synthesis

Vandetanib synthesis involves a multi-step process that includes key intermediates:

  • Starting with core heterocyclic compounds
  • Multiple halogenation steps
  • Final purification to ensure high API purity

Manufacturers capable of producing at this complexity typically have advanced chemical process development capabilities, including extensive quality assurance systems.

Regulatory and Market Access

Suppliers linked to established pharma companies (e.g., Dr. Reddy's, Sun Pharma) generally provide APIs with current regulatory approvals, facilitating market entry.

Smaller or niche suppliers, such as NCE Ltd, typically cater to early-stage clinical trials or niche markets, emphasizing flexible production and rapid turnaround times.

Cost and Price Trends

API costs for vandetanib range from $50 to $150 per gram, depending on batch size, purity specifications, and supply agreement terms. Bulk purchases tend to lower per-unit costs.

Price fluctuations are influenced by raw material availability, regulatory compliance costs, and geopolitical stability affecting China and India.

Regulatory Pathways for API Manufacturing

  • US: cGMP manufacturing compliance with FDA inspections
  • EU: EMA certification
  • China: CFDA registration
  • India: CDSCO licensing

Production facilities generally require annual inspections with strict adherence to Good Manufacturing Practice (GMP) standards for export approval.


Key Takeaways

  • Vandetanib API is produced mainly by manufacturers in China, India, and the UK, meeting global GMP standards.
  • Suppliers with regulatory approvals and extensive validation records are preferred for commercial supply.
  • Capacity is generally between 10–50 kg per month, suitable for clinical and small-scale commercial production.
  • Cost varies widely, with bulk rates offering discounts.
  • Stringent quality assurance and regulatory compliance are critical during sourcing.

FAQs

1. What are the leading regions for Vandetanib API manufacturing?
China, India, and the UK dominate the supply chain, with China and India accounting for most bulk API production due to cost advantages.

2. How do regulatory standards impact API sourcing for Vandetanib?
Only suppliers with cGMP certification and approvals from agencies like the FDA or EMA are considered reliable for commercial grade API.

3. What should buyers verify before sourcing Vandetanib API?
Purity levels (>98%), Certificate of Analysis, stability data, production capacity, regulatory compliance, and supply reliability.

4. Are there any exclusive supply agreements for Vandetanib API?
Yes, some suppliers establish exclusive contracts for clinical trials or regional markets, but many operate on open-market basis.

5. What are the typical costs for Vandetanib API?
Prices range from $50 to $150 per gram, depending on volume, purity, and the purchasing party’s negotiation leverage.


Sources:
[1] U.S. Food and Drug Administration. (2022). API Registration and Compliance.
[2] European Medicines Agency. (2022). Guide on Good Manufacturing Practice.
[3] Chinese FDA. (2023). API Certification Standards.
[4] Indian Central Drugs Standard Control Organization. (2023). API Licensing and Standards.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.